ライフサイエンスコーパス: platelet-activating factor

1 ulation of a G-protein coupled receptor with platelet activating factor.

2 significantly inhibited the biosynthesis of platelet activating factor.

3 hingomyelin (SM) to ceramide and inactivates platelet activating factor.

4 y alcohols, which are possible precursors of platelet activating factor.

5 is induced by administration of histamine or platelet-activating factor.

6 rmation was also reversed by the addition of platelet-activating factor.

7 trates for the production of eicosanoids and platelet-activating factor.

8 -containing lipids, such as lyso-PC, PC, and platelet-activating factor.

9 2-AG) are unaffected by LPS but increased by platelet-activating factor.

10 human epithelial cells via the receptor for platelet-activating factor.

11 ector cells, and the mediators histamine and platelet-activating factor.

12 ins in whole blood and dampened responses to platelet-activating factor.

13 ed priming of this response by TNF-alpha and platelet-activating factor.

14 owing to elevated levels of pro-inflammatory platelet-activating factors.

15 Platelet-activating factor (1-alkyl-2-acetyl-3-glyceroph

16 Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycer

17 els for 1 hour and intraluminal injection of platelet activating factor (50 micro/kg).

18 that were 50-70% of those induced by 100 nM platelet-activating factor, a positive control.

19 toxic injury via activation of receptors for platelet-activating factor, a proinflammatory signaling

20 tic oxidatively truncated phospholipids, and platelet-activating factor, a remarkably potent and plei

21 Low platelet activating factor acetyl hydrolase activity was

22 oluble tumor necrosis factor receptor I, and platelet activating factor acetyl hydrolase.

23 with the HDL-associated enzymes paraoxonase, platelet activating factor acetylhydrolase (PAF), and gl

24 nts, the most potent effect was observed for platelet activating factor acetylhydrolase alpha (Paf-AH

25 gulation of expression of the plasma form of platelet-activating factor acetylhydrolase (PAF AH) in t

26 Platelet-activating factor acetylhydrolase (PAF-AH) is a

27 The enzyme platelet-activating factor acetylhydrolase (PAF-AH) rapi

28 or was inactivated by alkaline hydrolysis or platelet-activating factor acetylhydrolase (PAF-AH) trea

29 the possibility that the activity represents platelet-activating factor acetylhydrolase (PAF-AH), an

30 We report that platelet-activating factor acetylhydrolase (PAFAH) Ib, c

31 t that the cytoplasmic PLA(2) enzyme complex platelet-activating factor acetylhydrolase (PAFAH) Ib, w

32 fective milk containing diminished levels of platelet-activating factor acetylhydrolase (PAFAH).

33 Platelet-activating factor acetylhydrolase (PLA2G7) is a

34 roteins such as alpha-N-catenin (CTNNA2) and platelet-activating factor acetylhydrolase 1b regulatory

35 Platelet-activating factor acetylhydrolase 1B1 (LIS1), a

36 eration by ectopic expression of PL-specific platelet-activating factor acetylhydrolase 2 (PAFAH2) ma

37 lycopene), and antioxidant enzyme activity (platelet-activating factor acetylhydrolase [PAF-AH] and

38 A recent report demonstrates that plasma platelet-activating factor acetylhydrolase activity incr

39 om allergy, such as suggesting that baseline platelet-activating factor acetylhydrolase activity leve

40 Measurement of platelet-activating factor acetylhydrolase activity repr

41 ll dense low-density lipoproteins, increased platelet-activating factor acetylhydrolase activity, and

42 Plasma platelet-activating factor acetylhydrolase becomes progr

43 lesterolemic human plasma with a recombinant platelet-activating factor acetylhydrolase completely ab

44 izygous mutations in the human gene encoding platelet-activating factor acetylhydrolase IB subunit al

45 The activities of paraoxonase and platelet-activating factor acetylhydrolase in HDL decrea

46 imal study, transfection of tumor cells with platelet-activating factor acetylhydrolase inhibited tum

47 nt controversy over whether paraoxonase 1 or platelet-activating factor acetylhydrolase is responsibl

48 rpose of this study was to determine whether platelet-activating factor acetylhydrolase Sse and strep

49 creened by enzymatic assays for SpeB and the platelet-activating factor acetylhydrolase Sse, and a ne

50 coding complement component receptor 2/CD21, platelet-activating factor acetylhydrolase, and oxidized

51 tions in the relative levels of paraoxonase, platelet-activating factor acetylhydrolase, ceruloplasmi

52 n-associated phospholipase A2, also known as platelet-activating factor acetylhydrolase, is a new ris

53 lation and elongation protein zeta-1 (FEZ1), platelet-activating factor acetylhydrolase, isoform Ib,

54 e inconclusive in determining whether plasma platelet-activating factor acetylhydrolase, or lipoprote

55 nzymes, BChE and a new extracellular form of platelet-activating factor acetylhydrolase, PAFAH1b2.

56 ated phospholipase A2 (Lp-PLA2), also called platelet-activating factor acetylhydrolase, plays in ath

57 Lp-PLA2, also known as platelet-activating factor acetylhydrolase, rapidly clea

58 hospholipase A(2) (Lp-PLA(2)), also known as platelet-activating factor acetylhydrolase.

59 ted protein and as one subunit of the enzyme platelet-activating factor acetylhydrolase.

60 Platelet-activating factor acetylhydrolases (PAF-AHs) ar

61 In vivo and in vitro histamine and platelet-activating factor administration increases Fn14

62 Finally, Tat and platelet-activating factor also increased neuronal vesic

63 ory cellular metabolite up-regulated by Tat, platelet-activating factor, also induced oxidative stres

64 We report that platelet-activating factor, an inflammatory phospholipid

65 In hippocampal slices exposed to a stable platelet-activating factor analogue, tetanic stimulation

66 mesangial cell line induced upregulation of platelet activating factor and the fibrotic marker TGF-b

67 As platelet-activating factor and HPC share structural semb

68 on anaphylaxis suggest an important role for platelet-activating factor and its relationship to the n

69 flammatory mediators (tumor necrosis factor, platelet-activating factor and prostaglandins), studies

70 ng receptors for chemokines, PGs, histamine, platelet activating factor, and anaphylatoxin.

71 ith N-formyl-methionyl-leucyl-phenylalanine, platelet activating factor, and leukotriene B4 was phosp

72 ory G protein-coupled chemoattractants fMLP, platelet-activating factor, and IL-8 elicit unique patte

73 ipids, including sphingosine, sphingomyelin, platelet-activating factor, and lysophosphatidylcholine.

74 Lysophosphatidylcholine, lyso-platelet-activating factor, and several phospholipid fat

75 production induced by TNF-alpha, GM-CSF, and platelet-activating factor, and this loss of pyk2 activi

76 locked by a combination of antihistamine and platelet-activating factor antagonist (but neither alone

77 e mediated by the autocrine activity, not of platelet-activating factor, but rather of endogenous CCR

78 d to surrogate PMNs respond to activation by platelet activating factor by initiating translation and

79 Tsujimura et al. report that the release of platelet-activating factor by basophils stimulated with

80 arturition signals, surfactant protein A and platelet-activating factor, by the developing mouse feta

81 uding vascular endothelial growth factor and platelet-activating factor; by contrast, endothelial cel

82 d immunoglobulins (IgG, IgA), cytokines with platelet activating factor, calcium ionophore, or phorbo

83 irway eosinophils to chemoattractants (FMLP, platelet-activating factor, CCL11, CCL5, CXCL8) with res

84 se in cytosolic Ca2+ whereas the addition of platelet-activating factor did.

85 as prior exposure to a p38-activating agent (platelet-activating factor) diminished the TNFalpha-indu

86 cellular calcium concentration stimulated by platelet-activating factor, fMLP, and SP-G.

87 some of these peptides (eg, endothelin-1 and platelet-activating factor) has decreased mortality and

88 surfactant phospholipids and biosynthesis of platelet-activating factor in noninflammatory remodeling

89 -third, suggesting a role for toxin-produced platelet-activating factor in this process.

90 via CD14-, NF-kappaB-, and p44/42-dependent, platelet-activating factor-independent activation of the

91 ogen synthase kinase 3beta inhibitor, blocks platelet activating factor-induced activation of glycoge

92 otected primary astrocytes from H(2)O(2)- or platelet-activating factor-induced apoptosis.

93 In ADSA lymphoblasts, platelet-activating factor-induced Ca(2+) mobilization w

94 ependent manner, LXs significantly inhibited platelet-activating factor-induced increases in leukocyt

95 Following platelet-activating factor-induced shock, MK886 increase

96 TWEAK-blocking antibody prevented histamine/platelet-activating factor-induced vascular subcutaneous

97 NET formation after stimulation with platelet activating factor, ionomycin, or phorbol 12-myr

98 Using our model, we also show that platelet-activating factor is a crucial mediator of both

99 duction of prostaglandins, leukotrienes, and platelet-activating factor, is present in EAE lesions.

100 gosine blocks thapsigargin-, ionomycin-, and platelet-activating factor-mediated SOCE despite normal

101 ceptor antagonists, or overexpression of the platelet-activating factor metabolizing enzyme acetylhyd

102 depletion by the G protein-coupled agonists platelet-activating factor or fMLP, but abolished agonis

103 tional state, and subsequent activation with platelet-activating factor or formyl-methionyl-leucyl-ph

104 Furthermore, platelet-activating factor or interleukin 8 acted in con

105 ormally sensitive to substance P, but not to platelet-activating factor or serotonin, suggesting that

106 merous chemoattractants, such as chemokines, platelet-activating factor, or FMLP, through a process k

107 ls with G protein-coupled receptor agonists, platelet-activating factor, or FMLP.

108 mediators, including TNF-alpha, GM-CSF, and platelet-activating factor, overcomes the adhesion-media

109 The platelet activating factor (PAF) acetyl hydrolase 1b (Pa

110 alyzes the hydrolytic inactivation of plasma platelet activating factor (PAF) and is also known as PA

111 Platelet activating factor (PAF) and PAF-like lipids ind

112 as well as resveratrol and quercetin, on the platelet activating factor (PAF) biosynthetic enzymes, a

113 plexed with the physiological ligand GM2 and platelet activating factor (PAF) have shown binding at t

114 Platelet activating factor (PAF) interacts with cell sur

115 Platelet activating factor (PAF) is a potent inflammator

116 Platelet activating factor (PAF) is a potent lipid autoc

117 tenuate the permeability increase induced by platelet activating factor (PAF) or bradykinin.

118 dministered with either the HIV-1 neurotoxin platelet activating factor (PAF) or the regulatory HIV-1

119 th BN52021, WEB-2170, and WEB-2086 (specific platelet activating factor (PAF) receptor antagonists),

120 Both LPS and BLP stimulated the synthesis of platelet activating factor (PAF), a potent lipid mediato

121 rved that tumor necrosis factor (TNF)-alpha, platelet activating factor (PAF), and lipopolysaccharide

122 rmyl-methionyl-leucyl-phenylalanine (fMLP)), platelet activating factor (PAF), leukotriene B4 (LTB(4)

123 mbination with uridine 5'-diphosphate (UDP), platelet activating factor (PAF), or lysophosphatidic ac

124 incubated in H2O2 (70 micromol/L, 2 hours), platelet activating factor (PAF), prostaglandin E2 (PGE2

125 ion and chemoattraction, Mig potently blocks platelet activating factor (PAF)- and leukotriene B4 (LT

126 A crystal structure of GM2-AP complexed with platelet activating factor (PAF).

127 se, neutrophil activation in the presence of platelet activating factor (PAF).

128 ed for lysophosphatidylcholine (lysoPCh) and platelet activating factor (PAF).

129 Platelet-activating factor (PAF [1-O-alkyl-2-acetyl-sn-g

130 The plasma form of platelet-activating factor (PAF) acetylhydrolase (PAF-AH

131 Human plasma platelet-activating factor (PAF) acetylhydrolase functio

132 low density lipoprotein and comigrates with platelet-activating factor (PAF) acetylhydrolase on KBr

133 The platelet-activating factor (PAF) acetylhydrolase SsE pro

134 the PAFAH1B2 and PAFAH1B3 subunits of type I platelet-activating factor (PAF) acetylhydrolase, a phos

135 UV-induced keratinocyte-derived platelet-activating factor (PAF) activates mast cell mig

136 idized glycerophosphocholines (Ox-GPCs) with platelet-activating factor (PAF) activity produced non-e

137 uction of glycerophosphocholines that act as platelet-activating factor (PAF) agonists.

138 er short-chained phospholipids--inflammatory platelet-activating factor (PAF) and apoptotic oxidative

139 genesis and photoimmune suppression, such as platelet-activating factor (PAF) and serotonin (5-HT) re

140 Platelet-activating factor (PAF) and structurally-relate

141 perties of the yoghurts PL fractions against platelet-activating factor (PAF) and thrombin-induced pl

142 GS4, also blocked phosphorylation of PAFR by platelet-activating factor (PAF) and, unexpectedly, by p

143 Species related to platelet-activating factor (PAF) and/or lyso-phosphatidy

144 Treatment with platelet-activating factor (PAF) antagonists also reduce

145 Over the past few years, the role of platelet-activating factor (PAF) as a potent mediator in

146 We used platelet-activating factor (PAF) as a proinflammatory ag

147 models and human asthmatics have implicated platelet-activating factor (PAF) as an important inflamm

148 r wild-type control as experimental animals, platelet-activating factor (PAF) at 10(-7) m as the test

149 ponses to the inflammatory mediators C5a and platelet-activating factor (PAF) but did not respond to

150 Platelet-activating factor (PAF) causes wheal and flare

151 at cigarette smoking leads to an increase in platelet-activating factor (PAF) content and PAF recepto

152 ured spleen and liver cytokine responses and platelet-activating factor (PAF) content in mice given C

153 -2) regulate surfactant protein-A (SP-A) and platelet-activating factor (PAF) expression, which incre

154 ittle, if any, role in neutrophil priming by platelet-activating factor (PAF) for OpZ-dependent respo

155 Platelet-activating factor (PAF) has been shown to affec

156 at exposure of neutrophils to E-selectin and platelet-activating factor (PAF) in combination induced

157 In the current study, the role of platelet-activating factor (PAF) in combination with tum

158 t studies have implicated the lipid mediator platelet-activating factor (PAF) in UVB-mediated systemi

159 models of LE that the phospholipid mediator platelet-activating factor (PAF) increases in LE and tha

160 Platelet-activating factor (PAF) increases permeability

161 It is known that platelet-activating factor (PAF) induces severe endothel

162 Evidence suggests that platelet-activating factor (PAF) is a mediator in inflam

163 Platelet-activating factor (PAF) is a mediator of inflam

164 Platelet-activating factor (PAF) is a naturally occurrin

165 Platelet-activating factor (PAF) is a phospholipid media

166 Platelet-activating factor (PAF) is a phospholipid with

167 In this study, we demonstrate that platelet-activating factor (PAF) is a potent inducer of

168 Platelet-activating factor (PAF) is a potent lipid media

169 Platelet-activating factor (PAF) is a potent phospholipi

170 Platelet-activating factor (PAF) is a potent proinflamma

171 Platelet-activating factor (PAF) is a potent proinflamma

172 Platelet-activating factor (PAF) is a potent proinflamma

173 Platelet-activating factor (PAF) is a potent, bioactive

174 Platelet-activating factor (PAF) is a powerful proinflam

175 Platelet-activating factor (PAF) is a proinflammatory ph

176 Because platelet-activating factor (PAF) is a proximal mediator

177 Platelet-activating factor (PAF) is an important mediato

178 The phospholipid platelet-activating factor (PAF) is an important mediato

179 tors of inflammation are not identified, but platelet-activating factor (PAF) is implicated as a pote

180 Platelet-activating factor (PAF) is implicated in the ca

181 Because the lipid mediator of inflammation, platelet-activating factor (PAF) is released by UV-irrad

182 Animal models show that the receptor for platelet-activating factor (PAF) is responsible for many

183 Although the lipid mediator platelet-activating factor (PAF) is synthesized in respo

184 Although the lipid mediator platelet-activating factor (PAF) is synthesized in respo

185 Though the lipid mediator platelet-activating factor (PAF) is synthesized in respo

186 Platelet-activating factor (PAF) mediates an array of bi

187 Animal and human data show that platelet-activating factor (PAF) mediates the life-threa

188 ry potential of the proinflammatory mediator platelet-activating factor (PAF) on the subcellular dist

189 urvival after anaphylaxis, administration of platelet-activating factor (PAF) or histamine, and expos

190 th Kindlin-2 siRNA showed enhanced basal and platelet-activating factor (PAF) or lipopolysaccharide-s

191 esulted from inhibitory signals generated by platelet-activating factor (PAF) or oxidized LDL that ac

192 ncreased AA and PGE2 release, accompanied by platelet-activating factor (PAF) production.

193 We hypothesize that platelet-activating factor (PAF) receptor (PAFR) ligatio

194 LAU-0901, a novel platelet-activating factor (PAF) receptor antagonist, is

195 regation was inhibited by antagonists of the platelet-activating factor (PAF) receptor but not inhibi

196 tor and that antagonists of 5-HT(2A) and the platelet-activating factor (PAF) receptor can block cis-

197 f intracellular Leishmania, we surmised that platelet-activating factor (PAF) receptor had a signific

198 Activation of the platelet-activating factor (PAF) receptor leads to a dec

199 onist of the PTX-sensitive G protein-coupled platelet-activating factor (PAF) receptor, blocked the a

200 Corneal stromal myofibroblasts express the platelet-activating factor (PAF) receptor, but its role

201 ba extracts and are known antagonists of the platelet-activating factor (PAF) receptor.

202 Ginkgolides are known antagonists of the platelet-activating factor (PAF) receptor.

203 igated for their ability to bind to a cloned platelet-activating factor (PAF) receptor.

204 These studies examined the role of the platelet-activating factor (PAF) signaling system in UVB

205 Previously, we reported that platelet-activating factor (PAF) stimulates higher G pro

206 ne suppression are the binding of UV-induced platelet-activating factor (PAF) to its receptor and the

207 and the proinflammatory glycerophospholipid platelet-activating factor (PAF) were markedly reduced i

208 cell types with respect to the metabolism of platelet-activating factor (PAF), a biologically active

209 s by exploiting molecular mimicry to degrade platelet-activating factor (PAF), a host-derived inflamm

210 Platelet-activating factor (PAF), a phospholipid second

211 We analyzed the effect of platelet-activating factor (PAF), a potent phospholipid

212 Recent studies suggest that the action of platelet-activating factor (PAF), a potent phospholipid

213 Platelet-activating factor (PAF), a potent phospholipid

214 ated endocytosis (CME), we hypothesized that platelet-activating factor (PAF), an effective chemoattr

215 in corneal epithelial cells stimulated with platelet-activating factor (PAF), and interferes with th

216 ctively induced by the addition of PGE(2) or platelet-activating factor (PAF), another lipid cytokine

217 UVB radiation generates the lipid mediator, platelet-activating factor (PAF), as well as oxidized ph

218 nergistic signaling induced by serotonin and platelet-activating factor (PAF), but not histamine.

219 The phospholipid, platelet-activating factor (PAF), exerts multiple physio

220 Leu-Phe (fMLP), adenosine diphosphate (ADP), platelet-activating factor (PAF), interleukin-8 (IL-8),

221 shown that the lipid inflammatory mediator, platelet-activating factor (PAF), synthesized by activat

222 mbrane inhibits hyperpermeability induced by platelet-activating factor (PAF), VEGF in ECV-CD8eNOSGFP

223 e calcium entry (SOCE) following the initial platelet-activating factor (PAF)-induced release of Ca(2

224 Degrading platelet-activating factor (PAF)-like lipids in L5 by a

225 ults in the production of the lipid mediator platelet-activating factor (PAF).

226 roduction of prostaglandin I(2) (PGI(2)) and platelet-activating factor (PAF).

227 is mediated, in part, by the lipid mediator platelet-activating factor (PAF).

228 rat small intestine and is down-regulated by platelet-activating factor (PAF).

229 secrete the lipid mediator of inflammation, platelet-activating factor (PAF).

230 P) protects mice from lethal challenges with platelet-activating factor (PAF).

231 rete the inflammatory phospholipid mediator, platelet-activating factor (PAF).

232 mediators, including adhesion molecules and platelet-activating factor (PAF).

233 phospholipids and the inflammatory mediator platelet-activating factor (PAF).

234 eparations with or without pretreatment with platelet-activating factor (PAF).

235 reduces neutrophil recruitment by targeting platelet-activating factor (PAF).

236 Among the proinflammatory mediators, platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-g

237 -alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor, PAF) and the generation of 2

238 diated responses, RGS4 and the receptors for platelet-activating factor (PAFR), formylated peptides (

239 hown that the protein acts primarily as lyso-platelet-activating factor-phospholipase C.

240 phils were treated with fMLP with or without platelet-activating factor, PMA alone, or tumor necrosis

241 nitiates the biosynthesis of eicosanoids and platelet-activating factor, potent mediators of inflamma

242 Under the same experimental conditions, platelet-activating factor primed neutrophils for supero

243 factor, the ability of alpha-toxin to induce platelet-activating factor production was assessed, and

244 regation was blocked using a monoclonal anti-platelet activating factor receptor (PafR) antibody and

245 Here, we examined the role of platelet activating factor receptor (PAFR) in colitis-as

246 ine, an H1R antagonist, blocked EAE, and the platelet activating factor receptor antagonist CV6209 re

247 creased adherence mediated by binding to the platelet activating factor receptor on epithelial cells.

248 d receptor-1, protease activated receptor-3, platelet activating factor receptor, and factor V.

249 D synthase, histamine receptor type 1 (H1R), platelet activating factor receptor, Ig Fc epsilon recep

250 eir ability to generate oxidized lipids with platelet-activating factor receptor (PAF-R) agonist acti

251 by generating oxidized lipid agonists of the platelet-activating factor receptor (PAF-R).

252 er of melanoma metastasis, via activation of platelet-activating factor receptor (PAFR) and cAMP-resp

253 dditional recognition system mediated by the platelet-activating factor receptor (PAFr) and directed

254 e hypothesis that influenza up-regulates the platelet-activating factor receptor (PAFr) and thereby p

255 Inhibitors of platelet-activating factor receptor (PAFR) blocked LTA-

256 We have previously shown that the Platelet-Activating Factor Receptor (PAFR) engagement in

257 The platelet-activating factor receptor (PAFr) has been sugg

258 hibitors identified a prominent role for the platelet-activating factor receptor (PAFr) in hypoxia-as

259 Platelet-activating factor receptor (PAFR) is a G protei

260 Platelet-activating factor receptor (PAFr) mediates pneu

261 f synaptic activity in a manner dependent on platelet-activating factor receptor (PAFR) signaling.

262 polymeric immunoglobulin receptor (pIgR) and platelet-activating factor receptor (PAFr) to attach and

263 iciency in interleukin 1alpha (IL-1alpha) or platelet-activating factor receptor (PAFR), an important

264 of A. baumannii binds to A549 cells through platelet-activating factor receptor (PAFR), resulting in

265 Moreover, expression of platelet-activating factor receptor (PAFR), which is kno

266 nvolved in immune responses include CD36 and platelet-activating factor receptor (PAFR).

267 r airway cells is mediated by host-expressed platelet-activating factor receptor (PAFR).

268 oupled receptors and excluded key candidates platelet-activating factor receptor and CCR5.

269 experiments revealed that L5 signals through platelet-activating factor receptor and lectin-like oxid

270 s demonstrate the differential expression of platelet-activating factor receptor and TLR-4 in uterine

271 nti-eotaxin and anti-RANTES mAbs, but not by platelet-activating factor receptor antagonists (CV6209,

272 Pretreatment of HaCaT cells with platelet-activating factor receptor antagonists, or over

273 Platelet-activating factor receptor blockade protected s

274 tion was assessed, and whether the epidermal platelet-activating factor receptor could augment toxin-

275 ctive effect resulted in part from decreased platelet-activating factor receptor expression on endoth

276 antibody or therapeutic agents that modulate platelet-activating factor receptor expression, may conf

277 stry studies demonstrate the presence of the platelet-activating factor receptor in both endometrial

278 nally, retroviral-mediated expression of the platelet-activating factor receptor into the platelet-ac

279 Anaphylaxis was inhibited by platelet-activating factor receptor or histamine recepto

280 milar involvement for an unrelated GPCR (the platelet-activating factor receptor), indicating that it

281 Bacterial lipoteichoic acid activates the platelet-activating factor receptor, which is G protein-

282 rom the international phase III trial of the platelet-activating factor receptor-antagonist Lexipafan

283 platelet-activating factor receptor into the platelet-activating factor receptor-negative epithelial

284 ent studies used model systems consisting of platelet-activating factor receptor-positive and -negati

285 signaling can be augmented via the epidermal platelet-activating factor receptor.

286 lin receptor, or cell wall phosphorylcholine/platelet-activating factor receptor.

287 holine residues on pneumococcal cell wall to platelet-activating factor receptor.

288 holine (ChoP), a ligand for the receptor for platelet-activating factor (rPAF).

289 ity, we found that histamine, serotonin, and platelet-activating factor, small molecule vascular perm

290 hil, macrophage, and neutrophil secretion of platelet-activating factor subsequent to FcgammaR stimul

291 of PMN cationic entry after thapsigargin or platelet-activating factor suggested that SOCE occurs th

292 lus for the synthesis for the lipid mediator platelet-activating factor, the ability of alpha-toxin t

293 Depletion of basophils and blockade of platelet-activating factor, the key components of the Ig

294 ructurally diverse neutrophil-priming agents platelet-activating factor, TNF-alpha, and the substance

295 rotein is rapidly synthesized in response to platelet activating factor under the control of a specia

296 Lysophosphatidylcholine and lyso-platelet-activating factor were also associated directly

297 nt chemicals (bradykinin, capsaicin, low pH, platelet-activating factor), whereas Adelta-fibres are r

298 5-hydroxytryptamine), platelet factor 4, and platelet-activating factor, which specifically stimulate

299 lpha-toxin resulted in significant levels of platelet-activating factor, which were approximately 50%

300 l, lipid mediators lysophosphatidic acid and platelet-activating factor, whose signals are implicated